Fisher & Paykel Healthcare Corporation (FPH) designs, manufactures and markets medical device products and systems for use in respiratory care, acute care and the treatment of obstructive sleep apnea. Its products include respiratory humidifiers, single-use and reusable chambers and breathing circuits, infant resuscitators, infant warmers and accessories. In addition, the company offers hardware and consumables. Fisher & Paykel’s segments include New Zealand, North America, Europe, and Asia-Pacific.
To ensure product quality and safety, FPH’s facilities have achieved ISO 13485 certification for quality management. The company encourages its suppliers to have their quality management systems certified to ISO 9001 or confirmed by an independent audit. As a result of these efforts, FPH has had limited recalls and no warning letters. The company is guided by an environmental policy which commits it to operate in a manner which prevents pollution; minimizes the impact of materials used in products and packaging; measures, reports and reduces carbon emissions; and educates its employees to meet the company’s environmental objectives. The company has upheld these guiding principles by achieving ISO 14001 certification at most of its production facilities. To reduce its direct footprint, FPH has installed solar PV stations and upgraded lighting systems at its facilities. The company has also set environmental reduction targets for its carbon emissions, energy use and waste. FPH demonstrates strong employee relations through its career planning programs and commitment to pay above any applicable minimum wage level.
Fisher & Paykal lacks take back initiatives. In addition, the company has limited transparency regarding the sustainability of its supply chain.
Industry: Health Care
Country: New Zealand
To the best of our knowledge the above information is accurate and was obtained from sources we believe to be reliable. Neither the information presented above nor any opinion expressed shall be construed as an offer to sell or a solicitation to buy the security. The views expressed are those of portfolio management as of 3/31/2017 and may not reflect current opinions or subsequent events.